Evidence that a novel dopamine receptor agonist, RDS-127 [2-di-n-propylamino-4,7-dimethoxyindane] has some centrally mediated cardiovascular actions.
The cardiovascular effects of RDS-127 [2-di-n-propylamino-4,7-dimethoxyindane] were examined in normotensive, anaesthetized rats. RDS-127 given i.v. (12.5-125 micrograms kg-1) produced dose-dependent bradycardia. The bradycardic effect was 20.5 times more potent when the drug was administered intracerebroventricularly (i.c.v.) than when given i.v. RDS-127 produced a slight, but significant hypotension. Haloperidol given i.c.v. or i.v. reversed these bradycardic and hypotensive actions, whereas phentolamine was ineffective. Methylatropine partially reduced the bradycardic effect. These results suggest that RDS-127 activates central DA receptors to produce hypotension and bradycardia in rats.
D000818:Animals; D001286:Atropine Derivatives / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000187:drug effects*; D004347:Drug Interactions; D006220:Haloperidol / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D007189:Indans / Q000008:administration & dosage / Q000494:pharmacology*; D007192:Indenes / Q000494:pharmacology*; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D010646:Phentolamine / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects*
D001286:Atropine Derivatives; D007189:Indans; D007192:Indenes; D011954:Receptors, Dopamine; C006649:methylatropine; C035604:2-N,N-di-n-propylamino-4,7-dimethoxyindan; D006220:Haloperidol; D010646:Phentolamine